Association between obesity and prescribed medication use in England |
| |
| Institution: | 1. Faculty of Medicine, University of Toronto, Toronto, Ontario, Canada;2. Faculty of Kinesiology and Physical Education, University of Toronto, Toronto, Ontario, Canada;3. St. Michael''s Hospital, University of Toronto, Toronto, Ontario, Canada;4. Division of Cardiology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada;1. Department of Cardiovascular and Metabolic Medicine, Institute of Life Course and Medical Sciences, University of Liverpool, Liverpool, United Kingdom;2. Department of Medicine, Liverpool University Hospitals NHS Foundation Trust, Liverpool, United Kingdom;3. School of Cancer Sciences, University of Birmingham, Birmingham, United Kingdom;4. Institute of Metabolism and Systems Research, University of Birmingham, Birmingham, United Kingdom;5. Department of Liver, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom;6. Department of Molecular and Clinical Cancer Medicine, Institute of Translational Medicine, University of Liverpool, Liverpool, United Kingdom |
| |
| Abstract: | We investigate the association between obesity and use of prescribed medications in England. Data were taken from fourteen rounds of the Health Survey for England (1999–2012), which has measures of current prescribed medication use based on therapeutic classifications in the British National Formulary, and nurse-measured height and weight. We find that obesity has a statistically significant and positive association with use of a range of medicines for managing diseases associated with obesity. The mean probability of using any type of medication is 0.40 in those of normal weight, 0.44 in the overweight, 0.52 in obesity class I and 0.60 in obesity class II/III. Significant positive associations were found between obesity and the use of medication for diseases of the cardiovascular system, gastrointestinal system, respiratory system, and central nervous system, as well as for infections, endocrine system disorders, gynaecological/urinary disorders and musculoskeletal and joint disorders. Use of anti-obesity medication is low, even among those with class II/III obesity. |
| |
| Keywords: | Obesity BMI Medication use England |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
